Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Drug Manufacturers - Specialty & Generic

Healthcare
$25.93 -0.71%

-$0.24 today

Market cap
$805.79M
Beta
0.75
P/E (TTM)
14.3
EPS (TTM)
$2.34
52W Low $29.19High $50.79

Volume 0.49M

Average 0.50M

COLL Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Collegium Pharmaceutical, Inc.NASDAQ: COLL

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 32.09M shares rose 0.9% year over year, ahead of the -1.1% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 1.2% from the prior quarter. Over 3 fiscal years it compounded at -2.1% a year.

Context

  • Weighted avg shares increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +0.9% holds above the trailing-twelve-month pace of -1.1%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
32.09M+1.2% QoQ
Last fiscal yearDec 2025
31.71M-1.8% YoY
LTMMar 2026
31.79M-1.1% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.9%——
1 year-1.8%——
3-year CAGR-2.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
31.71M USD
Year-over-year change
-1.8%
4-year CAGR
-2.4%

Weighted Avg Shares vs competitors

How COLL compares with its peers on the latest reported figures

  • COLL's LTM Mar 2026 weighted avg shares of 31.79M shares is the 2nd highest of the 3 companies compared; the peer median is 26.7M shares.
  • Its year-over-year change of -1.1% is the 2nd highest of 3, against a peer median of +27.1%.
  • Over three fiscal years its annual growth of -2.1% compares with a peer median of +20.8%.
COLL Competitors Peer median
Weighted Avg Shares for COLL and competitors
Company Period LTM YoY 3-year CAGR
PCRXPacira BioSciences, Inc.LTM Mar 202643.11M -6.7%-0.7%
COLLCollegium Pharmaceutical, Inc.LTM Mar 202631.79M -1.1%-2.1%
SCLXScilex Holding CompanyLTM Mar 202610.28M +60.8%+42.2%
LTGOLatigo Biotherapeutics Inc.—— ——
Peer median (excluding COLL) 26.7M+27.1%+20.8%

Competitors are the stored peer set for COLL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue276.87M463.93M566.77M631.45M780.57M
Cost of Revenue126.25M254.45M240.6M254.11M317.31M
Gross Profit150.62M209.49M326.17M377.34M463.26M
Gross Margin54.4%45.2%57.5%59.8%59.3%
Research & Development9.45M3.98M000
Selling, General & Admin118.96M172.19M159.21M182.98M276.17M
Operating Expenses132.99M176.17M159.21M207.45M276.17M
Depreciation & Amortization68.92M138.94M149.26M169.16M226.07M
EBITDA86.56M173.31M308.33M341.7M401.01M
EBITDA Margin31.3%37.4%54.4%54.1%51.4%
Operating Income17.63M33.32M166.96M169.9M187.08M
Operating Margin6.4%7.2%29.5%26.9%24.0%
Interest Income12K1.05M15.62M13.98M11.29M
Interest Expense21.01M63.21M83.34M73.97M82.31M
Other Income / Expenses(21M)(62.17M)(91.23M)(71.33M)(94.47M)
Income Before Tax(3.37M)(28.85M)75.73M98.57M92.62M
Pre-Tax Margin-1.2%-6.2%13.4%15.6%11.9%
Income Tax Expense(74.89M)(3.85M)27.58M29.38M29.75M
Net Income71.52M(25M)48.16M69.19M62.87M
Net Margin25.8%-5.4%8.5%11.0%8.1%
EPS (Basic)2.05(0.74)1.602.141.98
EPS (Diluted)1.86(0.74)1.291.861.73
Weighted Avg Shares34.94M33.83M33.74M32.27M31.71M
Weighted Avg Shares (Diluted)41.05M33.83M41.79M40.42M39.7M

Collegium Pharmaceutical, Inc.

NASDAQ:COLL

Intrinsic Alpha fair value

Locked

Current Price

$25.93

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.